Fig. 2
From: SLC22A3 methylation-mediated gene silencing predicts adverse prognosis in acute myeloid leukemia
Confirmation of SLC22A3 hypermethylation in AML. A SLC22A3 methylation density in controls, MDS and AML patients detected by targeted bisulfite sequencing. B The correlation of SLC22A3 methylation between two detection methods (RQ-MSP and targeted bisulfite sequencing). C SLC22A3 methylation level in larger cohort of controls, MDS and AML patients analyzed by RQ-MSP. D ROC curve analysis by SLC22A3 methylation for distinguishing AML patients from controls. **: P < 0.01; ***: P < 0.001